Scholarlink

<p>Nanotechnology has emerged as a promising field for developing innovative therapeutic strategies, including diabetes management. This study investigated the antidiabetic effects of zinc chloride (Zn) and the potential of zinc oxide nanoparticles (ZnO-NPs) in modulating blood glucose, biochemical parameters, kidney histopathology, and immunohistology in an alloxan-induced diabetic mouse model. Thirty male albino mice were divided into six groups: Negative Control (C), Diabetic Control (D), Diabetic + Zn (D + Z, 4 mg/kg. body weight), Negative Control + Zn (C + Z, 4 mg/kg b. w), Diabetic + ZnO-NPs (D + N, 4 mg/kg b. w), and Control + ZnO-NPs (C + N, 4 mg/kg b.w). Treatments were administered for 28 days, followed by blood and kidney tissue collection for histopathology and immunohistochemistry analysis. Our results show that Zinc chloride exhibited notable antidiabetic effects. On the other hand, while ZnO-NPs showed some negative changes, the results were not entirely conclusive, indicating that further research is needed to better understand their potential effects.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative Assessment of the Renal Effects of ZnO Nanoparticles Versus Zinc Chloride in Diabetic Mice: Biochemical and Histopathological Insights

  • 期刊论文

  • 发表日期：

    2025年9月26日

查看全文
  • Hedya Jemai,
  • Roua Ben Dassi,
  • Hachem Thabet,
  • Salah Ibidhi,
  • Sameh Hadj Taieb,
  • Monsef Feki,
  • Lassaad El Mir,
  • Ameur Cherif,
  • Rim Driouich Chaouachi

摘要

Nanotechnology has emerged as a promising field for developing innovative therapeutic strategies, including diabetes management. This study investigated the antidiabetic effects of zinc chloride (Zn) and the potential of zinc oxide nanoparticles (ZnO-NPs) in modulating blood glucose, biochemical parameters, kidney histopathology, and immunohistology in an alloxan-induced diabetic mouse model. Thirty male albino mice were divided into six groups: Negative Control (C), Diabetic Control (D), Diabetic + Zn (D + Z, 4 mg/kg. body weight), Negative Control + Zn (C + Z, 4 mg/kg b. w), Diabetic + ZnO-NPs (D + N, 4 mg/kg b. w), and Control + ZnO-NPs (C + N, 4 mg/kg b.w). Treatments were administered for 28 days, followed by blood and kidney tissue collection for histopathology and immunohistochemistry analysis. Our results show that Zinc chloride exhibited notable antidiabetic effects. On the other hand, while ZnO-NPs showed some negative changes, the results were not entirely conclusive, indicating that further research is needed to better understand their potential effects.

Graphical Abstract